HC Wainwright Has Optimistic Outlook of Liquidia Q2 Earnings

Liquidia Co. (NASDAQ:LQDA) – Analysts at HC Wainwright increased their Q2 2025 EPS estimates for shares of Liquidia in a research note issued on Monday, May 12th. HC Wainwright analyst A. Fein now expects that the company will earn ($0.41) per share for the quarter, up from their prior estimate of ($0.46). HC Wainwright currently has a “Buy” rating and a $29.00 target price on the stock. The consensus estimate for Liquidia’s current full-year earnings is ($1.51) per share. HC Wainwright also issued estimates for Liquidia’s Q3 2025 earnings at ($0.30) EPS, Q4 2025 earnings at ($0.23) EPS, FY2025 earnings at ($1.39) EPS, FY2026 earnings at ($0.82) EPS, FY2027 earnings at ($0.41) EPS, FY2028 earnings at ($0.04) EPS and FY2029 earnings at $0.54 EPS.

Liquidia (NASDAQ:LQDA) last posted its earnings results on Thursday, May 8th. The company reported ($0.45) earnings per share for the quarter, missing the consensus estimate of ($0.42) by ($0.03). Liquidia had a negative return on equity of 163.21% and a negative net margin of 765.38%. The firm had revenue of $3.12 million during the quarter, compared to the consensus estimate of $3.23 million.

A number of other brokerages have also commented on LQDA. Scotiabank reissued an “outperform” rating on shares of Liquidia in a report on Monday, May 5th. Needham & Company LLC restated a “buy” rating and set a $25.00 target price on shares of Liquidia in a research report on Monday. Finally, Raymond James upped their target price on shares of Liquidia from $27.00 to $29.00 and gave the company a “strong-buy” rating in a research report on Friday, May 9th. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, Liquidia presently has an average rating of “Buy” and an average price target of $27.13.

Liquidia Stock Up 3.5%

Shares of NASDAQ:LQDA opened at $19.30 on Thursday. Liquidia has a 12 month low of $8.26 and a 12 month high of $19.41. The company’s 50-day moving average price is $14.46 and its two-hundred day moving average price is $13.32. The firm has a market cap of $1.65 billion, a P/E ratio of -11.84 and a beta of 0.24.

Insider Transactions at Liquidia

In other news, insider Jason Adair sold 1,856 shares of the firm’s stock in a transaction that occurred on Monday, April 14th. The shares were sold at an average price of $13.57, for a total transaction of $25,185.92. Following the completion of the transaction, the insider now directly owns 184,304 shares of the company’s stock, valued at $2,501,005.28. This trade represents a 1.00% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, General Counsel Russell Schundler sold 5,964 shares of the firm’s stock in a transaction that occurred on Monday, April 14th. The stock was sold at an average price of $13.57, for a total transaction of $80,931.48. Following the transaction, the general counsel now directly owns 570,301 shares of the company’s stock, valued at $7,738,984.57. This represents a 1.03% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 33,138 shares of company stock valued at $450,233 in the last ninety days. 30.10% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Liquidia

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Corebridge Financial Inc. lifted its holdings in shares of Liquidia by 2.3% during the fourth quarter. Corebridge Financial Inc. now owns 31,516 shares of the company’s stock worth $371,000 after buying an additional 694 shares in the last quarter. Catalina Capital Group LLC raised its stake in Liquidia by 6.5% during the fourth quarter. Catalina Capital Group LLC now owns 18,307 shares of the company’s stock worth $215,000 after acquiring an additional 1,125 shares in the last quarter. GAMMA Investing LLC raised its stake in Liquidia by 65.6% during the first quarter. GAMMA Investing LLC now owns 2,961 shares of the company’s stock worth $44,000 after acquiring an additional 1,173 shares in the last quarter. Cetera Investment Advisers increased its stake in shares of Liquidia by 4.3% in the fourth quarter. Cetera Investment Advisers now owns 31,243 shares of the company’s stock valued at $367,000 after buying an additional 1,277 shares during the period. Finally, Valmark Advisers Inc. increased its stake in shares of Liquidia by 7.4% in the first quarter. Valmark Advisers Inc. now owns 18,641 shares of the company’s stock valued at $275,000 after buying an additional 1,283 shares during the period. 64.54% of the stock is owned by institutional investors.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).